Actively Recruiting

Phase 3
Age: 18Years - 45Years
FEMALE
NCT07524972

Antenatal Magnesium Sulphate in High-Risk Preterm Patients

Led by Cairo University · Updated on 2026-04-13

138

Participants Needed

1

Research Sites

108 weeks

Total Duration

On this page

Sponsors

C

Cairo University

Lead Sponsor

S

Suez Canal University

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this clinical trial is to evaluate whether antenatal magnesium sulphate reduces the risk of cerebral palsy in infants born to women at high risk of preterm birth. It will also assess the safety of magnesium sulfate for both the mother and the neonate. The main question it aims to answer is whether magnesium sulphate given before anticipated preterm delivery decreases the incidence of cerebral palsy without causing significant maternal or neonatal adverse effects. Researchers will compare magnesium sulphate with a placebo in women at high risk of preterm birth between 32 and 35 weeks of gestation. Participants will be randomly assigned to receive either intravenous magnesium sulphate or a placebo before delivery, and maternal and neonatal outcomes will be followed after birth, including neurodevelopmental assessment of the infant.

CONDITIONS

Official Title

Antenatal Magnesium Sulphate in High-Risk Preterm Patients

Who Can Participate

Age: 18Years - 45Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Pregnant women at high risk of preterm birth between 32 and 35 weeks of gestation
  • Birth is planned or expected within 24 hours
  • Singleton pregnancy
  • No contraindication to antenatal magnesium sulphate
  • Able to provide informed consent
Not Eligible

You will not qualify if you...

  • Higher-order multiple pregnancy
  • Received antenatal magnesium sulphate during the current pregnancy for hypertension or preeclampsia
  • Magnesium sulphate is required for treatment of preeclampsia
  • Second stage of labor
  • Respiratory rate less than 16 breaths per minute
  • Absent patellar reflexes
  • Urine output less than 100 mL in the previous 4 hours
  • Renal failure
  • Hypocalcemia
  • Myasthenia gravis
  • Magnesium sulphate infusion had to be stopped because of adverse effects

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Suez Canal University

Ismailia, Ismailia Governorate, Egypt, 8366004

Actively Recruiting

Loading map...

Research Team

M

mohamed shaaban, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here